TickerTalks
Browse all tickers →
TickerTalks›$ATAI
ATATAI

Atai Beckley Inc.

$ATAI·$2.7B·Biotechnology·Healthcare
$7.35+0.8%YTD+71.4%1Y+56.8%
Mentions · last 7 days
2026-08-21: 8 posts2026-08-22: 6 posts2026-08-23: 8 posts660%
Price updated 5m ago·X counts updated 8d ago
ATATAI
$ATAIAtai Beckley Inc.
$7.35+0.82%66 posts0%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $ATAI, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventEvent coming upAI verdict · as of 2026-08-30

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

AtaiBeckley trading as an Eli Lilly $6.75 cash + CVR arb — Kahn Swick investigating price adequacy is the potential upside.

AtaiBeckley (formerly Atai Life Sciences) is a $2.7B psychedelic-biotech merging with Eli Lilly at $6.75 cash + one CVR per share. Deal arb with a potential price-adequacy overhang.

How it reads:

  • Growth is not the story: Q1 revenue $1M (-38.6% YoY), the pipeline (ibogaine, psilocybin) is the whole asset — Lilly is buying the platform.
  • Fundamentals are clinical-stage: -37% operating margin, 82% gross, -8% FCF yield — the deal prices the option value.
  • Valuation is deal-anchored: -1.35x PE, 417x sales — every multiple prices the Lilly $6.75 base plus CVR upside, not standalone economics.
  • Position is stretched: 96th percentile 52w, 13.7% above 50-day, 58.9% above 200-day on 25% baseline volume — arb-tight range post-announcement.
  • The July 15 Lilly merger is the game: $6.75 cash at close plus one CVR — trading at $7.29 means the market prices the CVR at ~$0.54, and Kahn Swick investigating the price/process is the specific upside driver.
  • Apeiron Investment Group's 15.1% Amendment 4 is the specific block-shareholder position — no insider transactions (typical for a pending deal).
  • The bulls point to the 'road to Lilly' ibogaine story plus Rebellionaire 13F disclosure — but the deal is announced, so this is now a spread trade.

The next milestone is close or bump — a specific closing timeline plus reiterated CVR-milestone terms holds the spread; a Kahn Swick-driven bump higher extends upside; a milestone miss on the CVR pulls the stock to $6.75 base.

Agrees with X sentimentAgree — the bullish anchors (Rebellionaire 13F disclosure, psychedelic-bulletin radar, road to Lilly ibogaine story, PSIL ETF's 16K shares) map to real signals; the honest add is the trade is now the CVR value ($0.54 implied) plus any bump from the Kahn Swick investigation, not the standalone platform.

What to watch: Merger close or bump — a specific closing timeline plus reiterated CVR-milestone terms holds the spread; a Kahn Swick-driven price bump extends upside; a CVR-milestone miss pulls to the $6.75 base.

On the calendar: 2026-11-12 — Q3 earnings (interim to close)

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment⚠5 posts analyzed · as of 2026-08-14 · top-engagement diverged

Atai Life Sciences (now AtaiBeckley) is bullish. Rebellionaire 13F disclosed a new position, on the psychedelic-bulletin radar with the 'road to Lilly' ibogaine story, and PSIL ETF holds 16,000 shares. A single Hold downgrade at $8 appears but the accumulation and catalyst framing dominates.

Read the AI verdict + X sentiment for $ATAI

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech using psychedelic-derived compounds including psilocybin analogues to treat depression and addiction disorders.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $ATAI.

Biotechnology · Healthcare

GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.

What this means for $ATAI

Partial — fee-based midstream revenue has limited direct commodity price exposure but volume ties to upstream production activity.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+51.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-1.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-53.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-36.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-8.1%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
416.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-366%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
82.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 11, 2026$-0.09$-0.11+15.6%
Q1 2026May 12, 2026$-0.08$-0.11+27.3%
Q4 2025Mar 6, 2026$-0.05$-0.12+58.3%
Q3 2025Nov 12, 2025$-0.28$-0.12-133.3%
Next earningsThu, Nov 12·consensus EPS $-0.12

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$954K-38.6%82.5%-3239%$-0.13$-21.1M
Q4 FY25$1.1M-21420.0%100%-4032%$-2.45$-48.3M
Q3 FY25$749K+1772.5%68.9%-3797%$-0.28$-28.6M
Q2 FY25$719K+163.4%68.4%-3515%$-0.14$-19.2M

Forward consensus

5-year forecast · up to 11 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$1.4M$1.3M – $1.4M-$0.42-$0.70 – -$0.309
FY27$650K$643K – $660K-$0.43-$0.55 – -$0.247
FY28$813K$804K – $826K-$0.43-$0.63 – -$0.1811
FY29$79.3M$78.5M – $80.6M-$0.34-$0.35 – -$0.345
FY30$214.8M$212.5M – $218.3M-$0.19-$0.20 – -$0.195

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.2×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.96%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+13.7%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+58.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 201.0M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.3% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.555-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13D/AActivist amendmentJul 17SC 13D/A
AI summary

Apeiron Investment Group Ltd. (Malta) filed Amendment No. 4 to its Schedule 13D on July 17, 2026, disclosing an aggregate beneficial stake of 15.1% (55,770,948 shares, shared voting and dispositive power) in AtaiBeckley Inc. (ATAI) as of July 15, 2026; an associated entity, Apeiron Presight Capital Fund II, L.P., holds an additional 0.5% (1,799,302 shares). The 13D form (rather than a passive 13G) signals potential non-passive intent. This is a significant, potentially activist-linked ownership disclosure that warrants attention for ATAI shareholders.

8-KMaterial agreementJul 168-K — Item 1.01: Material agreement · Item 7.01: Press release / Reg FD
AI summary

AtaiBeckley Inc. (ATAI) signed a merger agreement on July 15, 2026 with Eli Lilly and Company, in which Lilly's subsidiary will acquire ATAI. Each share converts to $6.75 cash at closing plus one contingent value right (CVR) worth up to $2.50 per share upon specified clinical and regulatory milestones — for total consideration of up to $9.25 per share. The board unanimously approved the deal, which remains subject to customary closing conditions. This is a transformative acquisition by a top-five pharmaceutical company offering immediate cash liquidity plus milestone upside.

8-KShareholder voteJun 88-K — Item 5.07: Shareholder vote
AI summary

AtaiBeckley Inc. (ATAI) reported the results of its annual stockholder meeting held June 4, 2026, with 203,908,561 of approximately 366,916,896 eligible shares represented (a quorum). Three Class I directors — Sabrina Martucci Johnson, Amir Kalali M.D., and Andrea Heslin Smiley — were elected to serve through the 2029 annual meeting; Deloitte & Touche LLP was ratified as independent auditor for FY2026 with 201,864,060 votes in favor. All proposals passed. This is a routine annual meeting outcome with no surprises or contested votes.

8-KPress release / Reg FDJun 38-K — Item 7.01: Press release / Reg FD
AI summary

AtaiBeckley Inc. (ATAI) disclosed via Reg FD participation in four investor conferences in June 2026: Jefferies Global Healthcare (June 2-4, NYC), Oppenheimer CNS and Neuro-Muscular Summit (June 10, Miami), 7th Annual HCW Neuro Perspectives Hybrid Conference (June 15-16, virtual), and UBS Virtual CNS Day (June 15, virtual). Management planned to discuss program updates including initiation of the BPL-003 Phase 3 pivotal ReConnection program. The highlighted Phase 3 initiation is the most substantive signal for investors tracking the clinical pipeline.

3New insider — initial holdingsMar 133
8-KMaterial agreementMar 98-K — Item 1.01: Material agreement
S-3ASRAuto-shelf registrationMar 9S-3ASR
8-KPress release / Reg FDMar 68-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
+ 21 other (13 proxys · 2 10-Qs · 1 PREM14A · 1 13G) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAIgurufocus.com·3d agoAtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAIprnewswire.com·3d agoAre DSGR, HLX, ATAI, CRNX Obtaining Fair Deals for their Shareholders?gurufocus.com·14d agoAre DSGR, HLX, ATAI, CRNX Obtaining Fair Deals for their Shareholders?prnewswire.com·14d agoAtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAIgurufocus.com·14d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABCL
Voices on X · top 4 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport